More recent research looking at longer treatment periods shows that weight loss may continue over time, especially at higher doses: Weight loss in later trials (68 weeks, Phase 3) These later results suggest that with continued treatment, some people may lose even more weight than what was seen in earlier trials
If weight gain or height growth seems slow, physicians may adjust the treatment plan (for example, prescribing drug holidays on weekends or reducing the dose)
It is administered as a subcutaneous injection, typically at bedtime
Evidence shows these medications typically improve liver enzyme levels rather than harm them, particularly in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
If you experience digestive sensitivity, try moving the dose to the evening, at least two hours after your last meal
People who track their progress are much more likely to keep weight off